TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03012425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT01018550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 200 mg (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 25 mg (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 100 mg (BID)
Study: NCT03012425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diurnal Cortisol
Description: saliva test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diurnal Cortisol
Description: saliva test
Study: NCT01018550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04286607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical roflumilast
Description: Active treatment
Study: NCT03121677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized tumor vaccine
Description: * Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -The personalized tumor vaccine will be co-administered with poly-ICLC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Nivolumab will be administered at a dose of 240 mg intravenously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: * Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: -Other anti-CD20 mAb treatment can be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
Study: NCT03455920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical nurse (supernurse) evaluation
Description: The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonologist evaluation
Description: The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
Study: NCT00770289

Intervention type: OTHER
Intervention: Cohort
Description: Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
Study: NCT01128257

Intervention type: DRUG
Intervention: alendronate
Description: As prescribed by physician

Intervention type: DRUG
Intervention: ibandronate [Bonviva/Boniva]
Description: As prescribed by physician
Study: NCT02733991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™640G and Suspend before low
Description: All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiniMed™640G
Description: Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
Study: NCT04447261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356225
Description: BI 1356225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01588808

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: Immobilization with protein (elderlY), immobilization without protein (elderly and young)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Immobilization
Description: Immobilization with protein (elderlY), immobilization without protein (elderly and young)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: Immobilization with protein (elderlY), immobilization without protein (elderly and young)
Study: NCT02268864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
Study: NCT04162015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 360 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: cisplatin 75 mg/m2 or carboplatin AUC=5
Study: NCT01096225

Intervention type: BIOLOGICAL
Intervention: split-virion, H1N1 vaccine of 15 μg
Description: split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
Study: NCT01657045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100 or placebo
Description: Injections will be delivered depending on sternal incision length.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100 or placebo
Description: Injections will be delivered depending on sternal incision length.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100 or placebo
Description: Injections will be delivered depending on sternal incision length.
Study: NCT02377466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban IV infusion
Description: Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV infusion
Description: 0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
Study: NCT03894579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study Product: SNK01
Description: SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
Study: NCT01485770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX-N05
Description: 150 mg once a day for seven days followed by 300 mg once a day for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-N05
Description: 150 mg once a day for seven days followed by 300 mg once a day for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ADX-N05 once a day for 2 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match ADX-N05 once a day for 2 consecutive weeks
Study: NCT01860651

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-monitoring
Description: During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
Study: NCT02366520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handheld mirror
Description: The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
Study: NCT03791840

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound evaluation
Description: High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
Study: NCT00005937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
Study: NCT04023552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQJ230
Description: TQJ230 80 mg injected monthly administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
Study: NCT01678573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 250 mg/day tablet administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 250 mg/day tablet administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 250 mg/day tablet administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 500 mg/day tablets administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 500 mg/day tablets administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 500 mg/day tablets administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg/day tablets administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg/day tablets administered orally on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg/day tablets administered orally on Day 1 of each treatment period.
Study: NCT04446260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: be administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: be administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: be administered via intravenous (IV) infusion
Study: NCT03520075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Described above
Study: NCT02466958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levomilnacipran
Description: antidepressant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an inactive drug
Study: NCT02187276

Intervention type: DRUG
Intervention: cholinesterase inhibitors
Description: The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
Study: NCT04318483

Intervention type: OTHER
Intervention: survey
Description: parents' telephone interview to collect medical history

Intervention type: OTHER
Intervention: survey
Description: parents' telephone interview to collect medical history
Study: NCT04024813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: Capsule(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: Capsule(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: Capsule(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Seladelpar
Description: Capsule(s) administered orally once daily
Study: NCT03448393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22 CAR T-Cells
Description: CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22 CAR T-Cells
Description: CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
Study: NCT01364883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule One
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Two
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Three
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Four
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Five
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Six
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Seven
Description: AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
Study: NCT00774839

Intervention type: BEHAVIORAL
Intervention: Patient Interview
Description: The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
Study: NCT00005937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
Study: NCT03178981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
Study: NCT00764153

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar hemiarthroplasty
Description: Lateral approach. FWB.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal fixation
Description: Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
Study: NCT01020851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tailored intervention
Description: 6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention placebo
Description: 6 monthly telephone-delivered sessions focusing on general health topics
Study: NCT00742001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirasol System for Whole Blood.
Description: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirasol System for Whole Blood.
Description: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirasol System for Whole Blood.
Description: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
Study: NCT02312895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
Study: NCT03187262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
Study: NCT02277301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mellow Babies
Description: Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.